170 related articles for article (PubMed ID: 37478235)
1. Correlations between endometriosis, lipid profile, and estrogen levels.
Zheng R; Du X; Lei Y
Medicine (Baltimore); 2023 Jul; 102(29):e34348. PubMed ID: 37478235
[TBL] [Abstract][Full Text] [Related]
2. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
4. Differential diagnosis of ovarian cancer, benign ovarian tumor and endometriosis by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Takahashi K; Yoshino N; Karino K; Endoh J
Gynecol Obstet Invest; 1990; 29(1):71-4. PubMed ID: 1972127
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.
Nikolova T; Zivadinovic R; Evtimovska N; Klisarovska V; Stanojevic M; Georgievska J; Nikolova N
J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses.
Zheng H; Tie Y; Wang X; Yang Y; Wei X; Zhao X
Medicine (Baltimore); 2019 Feb; 98(7):e14577. PubMed ID: 30762809
[TBL] [Abstract][Full Text] [Related]
7. [Study on the predictive significance of PLR, SII and RPR in ovarian endometriotic cyst].
Li MM; Tang XH; Wang LM
Zhonghua Fu Chan Ke Za Zhi; 2023 Sep; 58(9):672-679. PubMed ID: 37724384
[No Abstract] [Full Text] [Related]
8. Diagnostic value of serum D-dimer, CA125, and neutrophil-to-lymphocyte ratio in differentiating ovarian cancer and endometriosis.
Chen L; Wang X; Shu J; Xu S; Wu Q; Yu Y
Int J Gynaecol Obstet; 2019 Nov; 147(2):212-218. PubMed ID: 31469423
[TBL] [Abstract][Full Text] [Related]
9. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
Zheng H; Gao Y
Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
[TBL] [Abstract][Full Text] [Related]
10. Comparison between Serum HE4 and CA125 as Tumor Markers in Premenopausal Women with Benign Pelvic Mass.
Huang X; Wang Y; He X; Kang F; Luo L; Su Z; Ye H
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115211
[TBL] [Abstract][Full Text] [Related]
11. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
12. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
13. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.
Anton C; Carvalho FM; Oliveira EI; Maciel GA; Baracat EC; Carvalho JP
Clinics (Sao Paulo); 2012; 67(5):437-41. PubMed ID: 22666786
[TBL] [Abstract][Full Text] [Related]
14. CYFRA 21-1 and Placental Growth Factor as Screening Markers for Endometriosis.
Cho HY; Kyung MS
Med Sci Monit; 2019 Feb; 25():1087-1092. PubMed ID: 30737365
[TBL] [Abstract][Full Text] [Related]
15. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients.
Braicu EI; Krause CL; Torsten U; Mecke H; Richter R; Hellmeyer L; Lanowska M; Müller B; Koch E; Boenneß-Zaloum J; Ames K; Chekerov R; Hasenbein K; Zimmermann M; Mangler M; Chen F; Tauber R; Sehouli J
BMC Cancer; 2022 Jul; 22(1):831. PubMed ID: 35907794
[TBL] [Abstract][Full Text] [Related]
16. Application of serum markers in diagnosis and staging of ovarian endometriosis.
Tang T; Lai H; Huang X; Gu L; Shi H
J Obstet Gynaecol Res; 2021 Apr; 47(4):1441-1450. PubMed ID: 33448139
[TBL] [Abstract][Full Text] [Related]
17. Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources.
Gidwani K; Nadeem N; Huhtinen K; Kekki H; Heinosalo T; Hynninen J; Perheentupa A; Poutanen M; Carpen O; Pettersson K; Lamminmäki U
J Appl Lab Med; 2019 Nov; 4(3):299-310. PubMed ID: 31659068
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ovarian cancer markers in endometriosis favours HE4 over CA125.
Mckinnon B; Mueller MD; Nirgianakis K; Bersinger NA
Mol Med Rep; 2015 Oct; 12(4):5179-84. PubMed ID: 26165164
[TBL] [Abstract][Full Text] [Related]
19. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
[TBL] [Abstract][Full Text] [Related]
20. [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors].
Liu YN; Ye X; Cheng HY; Cheng YX; Fu TY; Chen J; Chang XH; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):363-6. PubMed ID: 20646446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
